Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
EU WC
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 7-(3-amino-1-pyrrolidinyl)-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic Acid
2. 7-(3-aminopyrrolin-1-yl)-1-(2,4-diflurophenyl)-1.4-dihydro-6-fluoro-4-oxo-1,8-napthyridine-3-carboxylic Acid
3. A 60969
4. A 61827
5. A-60969
6. A-61827
7. A-64730
8. T 3262
9. T-3262
10. Tosufloxacin
11. Tosufloxacin Citric Anhydride
12. Tosufloxacin, 4-toluene Sulfonate
1. 1400591-39-0
2. Tosufloxacin Tosylate Hydrate
3. Tosufloxacin P-toluenesulfonate Hydrate
4. Tosuxacin
5. 107097-79-0
6. Ozex
7. Tosufloxacin Tosylate Monohydrate
8. Tosufloxacin (tosylate Hydrate)
9. 5l69lg8zdq
10. Tosufloxacin Tosilate Monohydrate
11. Tflx
12. 7-(3-aminopyrrolidin-1-yl)-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic Acid;4-methylbenzenesulfonic Acid;hydrate
13. Tosufloxacin Tosilate Hydrate
14. Tosuflo
15. Tosuxacin (tn)
16. Ozex (tn)
17. Tosufloxacintosylatehydrate
18. Unii-5l69lg8zdq
19. T-3262 Tosylate Hydrate
20. A-61827 Tosylate Hydrate
21. Schembl9478630
22. Rac-tosufloxacin Tosylate Hydrate
23. Tn-3262a
24. Chebi:32248
25. Hy-b1802a
26. (rs)-tosufloxacin Tosylate Hydrate
27. T-3262a
28. (+-)-tosufloxacin Tosylate Hydrate
29. Bcp13549
30. Tosufloxacin Monotosylate Monohydrate
31. Racemic Tosufloxacin Tosylate Hydrate
32. Mfcd00873760
33. S5299
34. Tosufloxacin Tosylate Hydrate (jp17)
35. Akos015914730
36. Ac-8909
37. Ccg-270179
38. Cs-5713
39. As-64106
40. Tosufloxacin Tosilate Hydrate [jan]
41. D01996
42. D92605
43. 097t790
44. Tosufloxacin Tosilate Monohydrate [who-dd]
45. Q27114837
46. A-61827 Tosylate Hydrate Pound>>a61827 Tosylate Hydrate Pound>>a 61827 Tosylate Hydrate;1400591-39-0
47. Rac-1-[6-carboxy-8-(2,4-difluorophenyl)-3-fluoro-5-oxo-5,8-dihydro-1,8-naphthyridin-2-yl]pyrrolidin-3-aminium 4-methylbenzenesulfonate--water (1/1)
48. Rac-7-(3-aminopyrrolidin-1-yl)-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic Acid 4-methylbenzenesulfonate--water (1/1)
| Molecular Weight | 594.6 g/mol |
|---|---|
| Molecular Formula | C26H25F3N4O7S |
| Hydrogen Bond Donor Count | 4 |
| Hydrogen Bond Acceptor Count | 14 |
| Rotatable Bond Count | 4 |
| Exact Mass | 594.13960481 g/mol |
| Monoisotopic Mass | 594.13960481 g/mol |
| Topological Polar Surface Area | 164 Ų |
| Heavy Atom Count | 41 |
| Formal Charge | 0 |
| Complexity | 915 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 1 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 3 |
ABOUT THIS PAGE
A Tosuxacin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Tosuxacin, including repackagers and relabelers. The FDA regulates Tosuxacin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Tosuxacin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Tosuxacin supplier is an individual or a company that provides Tosuxacin active pharmaceutical ingredient (API) or Tosuxacin finished formulations upon request. The Tosuxacin suppliers may include Tosuxacin API manufacturers, exporters, distributors and traders.
click here to find a list of Tosuxacin suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Tosuxacin Drug Master File in Japan (Tosuxacin JDMF) empowers Tosuxacin API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Tosuxacin JDMF during the approval evaluation for pharmaceutical products. At the time of Tosuxacin JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Tosuxacin suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Tosuxacin Drug Master File in Korea (Tosuxacin KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Tosuxacin. The MFDS reviews the Tosuxacin KDMF as part of the drug registration process and uses the information provided in the Tosuxacin KDMF to evaluate the safety and efficacy of the drug.
After submitting a Tosuxacin KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Tosuxacin API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Tosuxacin suppliers with KDMF on PharmaCompass.
Tosuxacin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Tosuxacin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Tosuxacin GMP manufacturer or Tosuxacin GMP API supplier for your needs.
A Tosuxacin CoA (Certificate of Analysis) is a formal document that attests to Tosuxacin's compliance with Tosuxacin specifications and serves as a tool for batch-level quality control.
Tosuxacin CoA mostly includes findings from lab analyses of a specific batch. For each Tosuxacin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Tosuxacin may be tested according to a variety of international standards, such as European Pharmacopoeia (Tosuxacin EP), Tosuxacin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Tosuxacin USP).
LOOKING FOR A SUPPLIER?
